The human immune system is a potentially powerful line of defense against cancer. Many biological obstacles exist in cancer patients that thwart tumor-specific T cell expansion, activation, tumor trafficking and killing. Among these is inadequate T cell precursor frequency and low T cell receptor (TCR) binding affinity for tumor antigen. Our hypothesis is that transplantation of high affinity TCR-transduced stem cells will create in the recipient an engineered immune system with potent antitumor biology. Thus, the single goal of this Program Project Grant (PPG) is to test this hypothesis by attempting to control or cure metastatic melanoma. This application is a key part of the strategy to arise from a 3-year collaboration among a score of investigators from four research universities (Caltech, UCLA, USC, UCONN) representing 4 cancer centers, 2 gene medicine programs, 13 departments and several institutes. Our research group will converge the disciplines of immunology, genetic engineering, stem ceil biology, virology, biological imaging and human gene medicine to engineer a tumor-specific human immune system. This will be accomplished in a PPG with 5 projects supported by 3 cores. The PPG will: (1) undertake two first-in-human clinical investigations in which a MART-1 melanoma antigen TCR will be introduced into T cells and hematopoietic stem cells using a lentiviral vector also expressing a PET reporter allowing serial noninvasive imaging of the development of an engineered immune system, (2) fundamental studies of the biology of TCR engineered hematopoietic and embryonic stem cells, and (3) basic biology of TCR engineering. State of the art cores in cell and gene therapy, immunological monitoring and biological imaging will support this science. In this PPG, basic and clinical science will be conducted in parallel, each informing the other;basic scientists and physician-scientists will work together as a team to develop discovery-based science that will change the care of patients.
Lay Summary: This large collaborative research program has as its goal to define the basic biology of genetically engineering the human immune system to recognize and destroy a deadly form of skin cancer - melanoma. Both preclinical animal and human clinical studies will be conducted to determine if blood stem cells can be engineered to produce cancer-killing white blood cells. While focusing on a single human , malignancy, scientific yield from this project will have a significant public health impact for other malignancies and infectious diseases.
|Fendler, Wolfgang Peter; Barrio, Martin; Spick, Claudio et al. (2016) 68Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessments: results from a prospective study on 50 patients. J Nucl Med :|
|Boschi, Stefano; Lee, Jason T; Beykan, Seval et al. (2016) Synthesis and preclinical evaluation of an Al(18)F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. Eur J Nucl Med Mol Imaging 43:2122-2130|
|Bethune, Michael T; Gee, Marvin H; Bunse, Mario et al. (2016) Domain-swapped T cell receptors improve the safety of TCR gene therapy. Elife 5:|
|Bluemel, Christina; Krebs, Markus; Polat, BÃ¼lent et al. (2016) 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clin Nucl Med 41:515-21|
|Fiacco, Stephen V; Kelderhouse, Lindsay E; Hardy, Amanda et al. (2016) Directed Evolution of Scanning Unnatural-Protease-Resistant (SUPR) Peptides for in Vivo Applications. Chembiochem 17:1643-51|
|Fendler, Wolfgang Peter; Czernin, Johannes; Herrmann, Ken et al. (2016) Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites. J Nucl Med 57:2016-2021|
|Spick, Claudio; Herrmann, Ken; Czernin, Johannes (2016) 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients. J Nucl Med 57:420-30|
|Fang, Jinxu; Hu, Biliang; Li, Si et al. (2016) A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma. Mol Ther Oncolytics 3:16007|
|Mok, Stephen; Tsoi, Jennifer; Koya, Richard C et al. (2015) Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer 15:356|
|Herrmann, Ken; Bluemel, Christina; Weineisen, Martina et al. (2015) Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med 56:855-61|
Showing the most recent 10 out of 58 publications